![Kate Millson MIScT BSc (Hons)](https://profiles-cardiff.imgix.net/attachments/936?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Trosolwg
Rwy'n rheolwr data ymchwil gyda phrofiad helaeth o gefnogi ymchwil iechyd meddwl a niwroseiciatrig ar raddfa fawr. Fel Rheolwr Data ar gyfer y Ganolfan Genedlaethol ar gyfer Iechyd Meddwl (NCMH), rwy'n goruchwylio llywodraethu, rheoli a defnyddio data ymchwil, gan helpu i sicrhau bod setiau data clinigol, demograffig a genomig cymhleth yn cael eu curadu, eu hygyrch a'u defnyddio'n gyfrifol.
Mae fy nghefndir yn cwmpasu rheoli data ymchwil, genomeg, ymchwil labordy a rheoli rhaglenni ymchwil, yn bennaf ar draws geneteg a genomeg niwroseiciatrig dynol, yn ogystal ag iechyd ac ecoleg. Yn ystod pandemig COVID-19, tra'n gweithio yn yr Hwb Ymchwil Genomeg, cyfrannais at ymdrechion dilyniannu genomig i gefnogi ymchwil SARS-CoV-2. Rwyf wedi cyfrannu at gydweithrediadau cenedlaethol a rhyngwladol mawr ac wedi cefnogi ymchwilwyr i wneud y mwyaf o werth eu data tra'n cynnal safonau uchel o lywodraethu a chydymffurfiaeth.
Yr hyn sy'n fy ysgogi yw'r wybodaeth y gall ymchwil wneud gwahaniaeth gwirioneddol i fywydau pobl. Mae fy ngyrfa wedi mynd â mi o gynhyrchu data genomig yn y labordy i reoli setiau data ymchwil cymhleth, gan roi persbectif unigryw i mi ar bwysigrwydd data o ansawdd uchel trwy gydol y broses ymchwil a'i rôl wrth alluogi darganfyddiad gwyddonol.
Cyhoeddiad
2026
- Gergel, T. et al., 2026. A tool to evaluate the impact of lived experience involvement in research: the Brain and Genomics Hub Impact Log protocol. Wellcome Open Research 11 562. (10.12688/wellcomeopenres.27426.1)
- Smart, S. E. et al. 2026. Genetics to Improve Outcomes in Schizophrenia (GENios): A within-case molecular genetic study protocol. PLoS ONE 21 (2) e0340584. (10.1371/journal.pone.0340584)
2025
- Nicolas, A. et al., 2025. Transferability of European-derived Alzheimer's disease polygenic risk scores across multiancestry populations. Nature Genetics 57 , pp.1598-1610. (10.1038/s41588-025-02227-w)
- Harvey, J. et al., 2025. Epigenetic insights into neuropsychiatric and cognitive symptoms in Parkinson's disease: A DNA co-methylation network analysis.. npj Parkinson's Disease 11 (1), pp.39. (10.1038/s41531-025-00877-5)
2024
- Tan, M. M. X. et al., 2024. Genome-wide determinants of mortality and motor progression in Parkinson’s disease. npj Parkinson's Disease 10 (1) 113. (10.1038/s41531-024-00729-8)
- Wu, L. Y. et al., 2024. Investigation of the genetic aetiology of Lewy body diseases with and without dementia. Brain Communications 6 (4) fcae190. (10.1093/braincomms/fcae190)
2023
- Real, R. et al., 2023. Association between the LRP1B and APOE loci in the development of Parkinson’s disease dementia. Brain 146 (5), pp.1873-1887. (10.1093/brain/awac414)
- Winchester, L. et al., 2023. Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluid. Brain Communications 5 (1) fcac343. (10.1093/braincomms/fcac343)
2022
- Willett, B. J. et al., 2022. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology 7 , pp.1161-1179. (10.1038/s41564-022-01143-7)
- Eales, O. et al., 2022. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2. BMC Infectious Diseases 22 (1) 647. (10.1186/s12879-022-07628-4)
- Nickbakhsh, S. et al., 2022. Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning. Scientific Reports 12 (1) 11735. (10.1038/s41598-022-15661-1)
- Kläser, K. et al., 2022. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Scientific Reports 12 (1) 10904. (10.1038/s41598-022-14016-0)
- Bellenguez, C. et al., 2022. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics 54 (4), pp.412-436. (10.1038/s41588-022-01024-z)
- Aggarwal, D. et al., 2022. Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications 13 1012. (10.1038/s41467-022-28371-z)
- Aggarwal, D. et al., 2022. Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications 13 (1) 751. (10.1038/s41467-021-27942-w)
2021
- de Rojas, I. et al., 2021. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications 12 (1) 3417. (10.1038/s41467-021-22491-8)
- Lythgoe, K. A. et al., 2021. SARS-CoV-2 within-host diversity and transmission. Science 372 (6539) eabg0821. (10.1126/science.abg0821)
- Davies, N. G. et al., 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372 (6538) eabg3055. (10.1126/science.abg3055)
- Tan, M. M. et al., 2021. Genome-wide association studies of cognitive and motor progression in Parkinson's disease. Movement Disorders 36 (2), pp.424-433. (10.1002/mds.28342)
2020
- Alm, E. et al., 2020. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance 25 (32) 2001410. (10.2807/1560-7917.ES.2020.25.32.2001410)
2019
- Tan, M. M. et al., 2019. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. Brain 142 (9), pp.2828-2844. (10.1093/brain/awz191)
2018
- Malek, N. et al., 2018. Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study. Journal of Neurology, Neurosurgery and Psychiatry 89 (7), pp.702-709. (10.1136/jnnp-2017-317348)
2016
- Malek, N. et al., 2016. Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. Acta Neurologica Scandinavica 134 (4), pp.271-276. (10.1111/ane.12538)
2015
- Malek, N. et al., 2015. Tracking Parkinson's: study design and baseline patient data. Journal of Parkinson's Disease 5 (4), pp.947-959. (10.3233/JPD-150662)
Articles
- Gergel, T. et al., 2026. A tool to evaluate the impact of lived experience involvement in research: the Brain and Genomics Hub Impact Log protocol. Wellcome Open Research 11 562. (10.12688/wellcomeopenres.27426.1)
- Smart, S. E. et al. 2026. Genetics to Improve Outcomes in Schizophrenia (GENios): A within-case molecular genetic study protocol. PLoS ONE 21 (2) e0340584. (10.1371/journal.pone.0340584)
- Nicolas, A. et al., 2025. Transferability of European-derived Alzheimer's disease polygenic risk scores across multiancestry populations. Nature Genetics 57 , pp.1598-1610. (10.1038/s41588-025-02227-w)
- Harvey, J. et al., 2025. Epigenetic insights into neuropsychiatric and cognitive symptoms in Parkinson's disease: A DNA co-methylation network analysis.. npj Parkinson's Disease 11 (1), pp.39. (10.1038/s41531-025-00877-5)
- Tan, M. M. X. et al., 2024. Genome-wide determinants of mortality and motor progression in Parkinson’s disease. npj Parkinson's Disease 10 (1) 113. (10.1038/s41531-024-00729-8)
- Wu, L. Y. et al., 2024. Investigation of the genetic aetiology of Lewy body diseases with and without dementia. Brain Communications 6 (4) fcae190. (10.1093/braincomms/fcae190)
- Real, R. et al., 2023. Association between the LRP1B and APOE loci in the development of Parkinson’s disease dementia. Brain 146 (5), pp.1873-1887. (10.1093/brain/awac414)
- Winchester, L. et al., 2023. Identification of a possible proteomic biomarker in Parkinson’s disease: discovery and replication in blood, brain and cerebrospinal fluid. Brain Communications 5 (1) fcac343. (10.1093/braincomms/fcac343)
- Willett, B. J. et al., 2022. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nature Microbiology 7 , pp.1161-1179. (10.1038/s41564-022-01143-7)
- Eales, O. et al., 2022. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2. BMC Infectious Diseases 22 (1) 647. (10.1186/s12879-022-07628-4)
- Nickbakhsh, S. et al., 2022. Genomic epidemiology of SARS-CoV-2 in a university outbreak setting and implications for public health planning. Scientific Reports 12 (1) 11735. (10.1038/s41598-022-15661-1)
- Kläser, K. et al., 2022. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Scientific Reports 12 (1) 10904. (10.1038/s41598-022-14016-0)
- Bellenguez, C. et al., 2022. New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics 54 (4), pp.412-436. (10.1038/s41588-022-01024-z)
- Aggarwal, D. et al., 2022. Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission. Nature Communications 13 1012. (10.1038/s41467-022-28371-z)
- Aggarwal, D. et al., 2022. Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications 13 (1) 751. (10.1038/s41467-021-27942-w)
- de Rojas, I. et al., 2021. Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications 12 (1) 3417. (10.1038/s41467-021-22491-8)
- Lythgoe, K. A. et al., 2021. SARS-CoV-2 within-host diversity and transmission. Science 372 (6539) eabg0821. (10.1126/science.abg0821)
- Davies, N. G. et al., 2021. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science 372 (6538) eabg3055. (10.1126/science.abg3055)
- Tan, M. M. et al., 2021. Genome-wide association studies of cognitive and motor progression in Parkinson's disease. Movement Disorders 36 (2), pp.424-433. (10.1002/mds.28342)
- Alm, E. et al., 2020. Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020. Eurosurveillance 25 (32) 2001410. (10.2807/1560-7917.ES.2020.25.32.2001410)
- Tan, M. M. et al., 2019. Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. Brain 142 (9), pp.2828-2844. (10.1093/brain/awz191)
- Malek, N. et al., 2018. Features of GBA-associated Parkinson's disease at presentation in the UK Tracking Parkinson's study. Journal of Neurology, Neurosurgery and Psychiatry 89 (7), pp.702-709. (10.1136/jnnp-2017-317348)
- Malek, N. et al., 2016. Olfaction in Parkin single and compound heterozygotes in a cohort of young onset Parkinson's disease patients. Acta Neurologica Scandinavica 134 (4), pp.271-276. (10.1111/ane.12538)
- Malek, N. et al., 2015. Tracking Parkinson's: study design and baseline patient data. Journal of Parkinson's Disease 5 (4), pp.947-959. (10.3233/JPD-150662)
Ymchwil
Diddordebau ymchwil
Mae fy ngwaith yn canolbwyntio ar reoli, llywodraethu a stiwardiaeth data ymchwil o fewn astudiaethau ymchwil iechyd meddwl a niwroseiciatrig ar raddfa fawr. Mae gen i ddiddordeb mewn sut mae rheoli data o ansawdd uchel yn cefnogi ymchwil gadarn, atgynhyrchadwy ac yn galluogi ymchwilwyr i ateb cwestiynau pwysig am achosion, canlyniadau a thriniaeth cyflyrau iechyd meddwl.
Ar ôl gweithio ar draws gwyddoniaeth labordy, genomeg a rheoli data, mae gen i ddiddordeb arbennig yng nghylch bywyd llawn data ymchwil, o gynhyrchu data a sicrhau ansawdd hyd at guradu, rhannu ac ailddefnyddio tymor hir.
Gwaith cyfredol
Fel Rheolwr Data ar gyfer y Ganolfan Genedlaethol ar gyfer Iechyd Meddwl (NCMH), rwy'n cefnogi rheoli a llywodraethu un o adnoddau ymchwil iechyd meddwl mwyaf y DU. Mae NCMH yn dwyn ynghyd wybodaeth gan filoedd o gyfranogwyr i helpu ymchwilwyr i ddeall cyflyrau iechyd meddwl yn well a datblygu dulliau gwell o ddiagnosis, triniaeth a chymorth.
Mae fy ngwaith yn cynnwys goruchwylio llywodraethu data, cefnogi mynediad ymchwilwyr at ddata, gweithredu prosesau rheoli data, a helpu i sicrhau bod data'n cael eu defnyddio'n gyfrifol ac yn effeithiol i wneud y mwyaf o effaith ymchwil.
Ymchwil gydweithredol
Trwy gydol fy ngyrfa rwyf wedi gweithio gydag ymchwilwyr, clinigwyr, gwyddonwyr data a gwyddonwyr labordy, yn y Brifysgol, ledled y DU ac yn rhyngwladol. Mae fy mhrofiad yn cwmpasu ymchwil iechyd meddwl, geneteg niwroseiciatrig a genomeg, dilyniannu cenhedlaeth nesaf ac un gell a rhaglenni ymchwil cydweithredol ar raddfa fawr.
Cymryd rhan mewn ymchwil
Mae ymchwil o ansawdd uchel yn dibynnu ar haelioni cyfranogwyr sy'n barod i gyfrannu eu hamser, eu profiadau a'u gwybodaeth i wella ein dealltwriaeth o iechyd a chlefydau.
Mae'r Ganolfan Genedlaethol ar gyfer Iechyd Meddwl yn ceisio cynnwys pobl sydd â phrofiad byw o gyflyrau iechyd meddwl, yn ogystal ag aelodau o'r teulu a gwirfoddolwyr, mewn ymchwil. Trwy gymryd rhan, gall unigolion helpu i lunio darganfyddiadau yn y dyfodol a chyfrannu at well dealltwriaeth, triniaeth a chefnogaeth ar gyfer cyflyrau iechyd meddwl.
Dysgwch fwy am gymryd rhan yn ymchwil NCMH: Y Ganolfan Genedlaethol ar gyfer Iechyd Meddwl (NCMH)
Bywgraffiad
2026 - presennol: Rheolwr Data, Canolfan Genedlaethol Iechyd Meddwl (NCMH)
2024 - 2026: Rheolwr Data, Grŵp Ymchwil Seicosis, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
2020 - 2024 Uwch Dechnegydd (Hwb Ymchwil Genome), Ysgol y Biowyddorau.
2019 - 2020: Rheolwr Ymchwil, Grŵp Ymchwil Alzheimer, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
2018 - 2019: Cydlynydd Sampl, Grŵp Ymchwil Alzheimer, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
2012 - 2018: Uwch Dechnegydd Ymchwil, Grŵp Ymchwil Parkinson, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
2010 - 2012: Technegydd Ymchwil, Cyfleuster Craidd, Is-adran Meddygaeth Seicolegol a Niwrowyddorau Clinigol
Anrhydeddau a dyfarniadau
Gwyddonydd Cofrestredig (RSci), a ddyfarnwyd gan y Cyngor Gwyddoniaeth (2018)
Aelodaethau proffesiynol
Aelod o'r Sefydliad Gwyddoniaeth a Thechnoleg
Contact Details
+44 29206 88362
Adeilad Hadyn Ellis, Llawr Llawr Cyntaf, Ystafell Swyddfa NCMH, Heol Maendy, Caerdydd, CF24 4HQ
Themâu ymchwil
Arbenigeddau
- Rheoli data
- Geneteg feddygol
- Genomeg
- Dilyniannu genom cyfan
- Rheoli prosiect